Curaleaf cultivates and sells cannabis in the US across 17 states through 19 cultivation sites and 151 dispensaries, with vertical integration enabling direct-to-consumer sales. The company returned to broad-based growth across domestic markets while experiencing strong international expansion despite a challenging pricing environment.
Cyborg Score Rationale
Curaleaf faces a persistently challenging pricing environment limiting growth momentum. The company carries substantial debt of $548.7 million against $101.6 million in cash as of December 31, 2025. However, international expansion and margin improvements provide offsetting strengths.
Top Insights
Q4 2025 revenue of $333 million increased 5% sequentially and 2% year-over-year despite challenging pricing.
International operations showed exceptional momentum with 65% YoY growth and 10% sequential Q4 growth.
Company discontinued hemp division and Missouri operations due to November 2025 federal legislation limiting THC levels.
Refinanced $500 million in senior secured notes due 2029, extending maturity and improving capital structure.
Named Competitors
Cannabis Retail & Cultivation — Leading US multistate cannabis operator